Free Trial

Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

-1.65 (-1.52%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
594,489 shs
Average Volume
620,851 shs
Market Capitalization
$6.74 billion
P/E Ratio
Dividend Yield
Price Target

Jazz Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.85 Rating Score
79.6% Upside
$192.75 Price Target
Short Interest
5.71% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.19mentions of Jazz Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$1.44 M Bought Last Quarter
Proj. Earnings Growth
From $15.38 to $18.21 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.97 out of 5 stars

Medical Sector

12th out of 921 stocks

Pharmaceutical Preparations Industry

4th out of 417 stocks

JAZZ stock logo

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Stock Price History

JAZZ Stock News Headlines

3 Cheap Blue-Chip Stocks to Buy Now: May 2024
7 Cannabis Stocks to Buy for a Smoking-Hot 2024
Jazz: Q1 Earnings Snapshot
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals: Cheap But Complicated
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
13 Analysts


Net Income
$414.83 million
Pretax Margin


Sales & Book Value

Annual Sales
$3.83 billion
Cash Flow
$27.43 per share
Book Value
$59.36 per share


Free Float
Market Cap
$6.78 billion

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

JAZZ Stock Analysis - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JAZZ shares.
View JAZZ analyst ratings
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price target for 2024?

13 Wall Street research analysts have issued 1-year target prices for Jazz Pharmaceuticals' shares. Their JAZZ share price targets range from $131.00 to $230.00. On average, they predict the company's share price to reach $192.75 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price.
View analysts price targets for JAZZ
or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2024?

Jazz Pharmaceuticals' stock was trading at $123.00 at the start of the year. Since then, JAZZ shares have decreased by 12.8% and is now trading at $107.30.
View the best growth stocks for 2024 here

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our JAZZ earnings forecast

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced its quarterly earnings data on Wednesday, February, 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.44 by $0.04. The specialty pharmaceutical company earned $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 27.86% and a net margin of 8.61%.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of 18.150-19.350 for the period, compared to the consensus earnings per share estimate of 18.930. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.23%), LSV Asset Management (3.78%), Polaris Capital Management LLC (2.27%), Capital World Investors (2.27%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.76%) and Perpetual Ltd (0.75%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Philip L Johnson, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce.
View institutional ownership trends

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
This page (NASDAQ:JAZZ) was last updated on 5/21/2024 by Staff

From Our Partners